title: Effects of dexamethasone on human trabecular meshwork cells in vitro.
abstract: OBJECTIVE
  To study the effects of dexamethasone sodium phosphate (Dex) on human trabecular meshwork (HTM) cells in vitro.
  
  
  METHODS
  HTM cells were treated with Dex 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.1 mg/ml, or 0.05 mg/ml for 24 h. Cell viability was measured by a trypan blue exclusion test. Caspase-3/7, -8, -9 and -12 activities were measured by fluorochrome assays as mean signal intensity (msi) to assess apoptosis. Mitochondrial dehydrogenase activity was determined by a WST assay to quantify mitochondrial damage.
  
  
  RESULTS
  Mean cell viabilities of HTM cells exposed to Dex at the higher doses of 2 mg/ml, 1 mg/ml, and 0.5 mg/ml were reduced: 11.9 % ± 3.5 (P < 0.001), 31.2 % ± 3.2 (P < 0.001), and 76.6 % ± 4.4 (P < 0.01). At the lower doses of 0.25 mg/ml, 0.1 mg/ml or 0.05 mg/ml, no significant cell viability reductions were seen: 96.3 % ± 0.7 (P > 0.05), 95.3 % ± 2.5 (P > 0.05) and 93.8 % ± 2.3 (P > 0.05), respectively compared to untreated HTM cells (97.0 % ± 1.9). Caspase-3/7 activity (msi) of HTM cells exposed to Dex 2, 1 or 0.5 mg/ml was 21068 ± 2498 (P < 0.001), 26994 ± 3104 (P < 0.001) and 20416 ± 1150 (P < 0.001) compared to untreated HTM cells 1148 ± 803. Caspase-9 activity (msi) of HTM cells after exposure to Dex 2, 1 or 0.5 mg/ml was 14188 ± 1203 (P < 0.001), 13256 ± 1564 (P < 0.001) and 15041 ± 1584 (P < 0.001) compared to untreated HTM cells 1748 ± 524. The lower doses of Dex did not significantly increase caspase-3/7 or -9 activities. There were no increases for caspase-8 or -12 activities at any of the tested Dex doses. The WST assay showed mitochondrial dehydrogenase activities of 14.3 ± 0.7 (P < 0.001), 9.6 ± 0.3 (P < 0.001) and 56.0 ± 7.6 (P < 0.001) at 2 mg/ml, 1 mg/ml and 0.5 mg/ml Dex compared to untreated HTM cells (186.1 ± 15.0).
  
  
  CONCLUSIONS
  Dex at 0.25, 0.1 and 0.05 mg/ml clinical dose did not cause significant reduction in cell viability, increased apoptosis, or mitochondrial dysfunction of HTM cells in vitro. At high doses (2, 1 or 0.5 mg/ml) Dex caused apoptosis via mitochondrial pathways.
authors: Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA. drashish79@hotmail.com
authors: Ashish
authors: A
authors: Sharma
authors: Alammaprabhu Jayaprakash
authors: AJ
authors: Patil
authors: Saffar
authors: S
authors: Mansoor
authors: Maria F
authors: MF
authors: Estrago-Franco
authors: Vincent
authors: V
authors: Raymond
authors: Maria Cristina
authors: MC
authors: Kenney
authors: Baruch D
authors: BD
authors: Kuppermann
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D020169:Caspases / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003124:Colorimetry; D003907:Dexamethasone / Q000494:pharmacology*; D042963:Electron Transport Complex II / Q000378:metabolism; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D014129:Trabecular Meshwork / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D042963:Electron Transport Complex II; D020169:Caspases
references: Arch Ophthalmol. 2007 Mar;125(3):309-17
references: 17353400
references: Prog Retin Eye Res. 1999 Sep;18(5):629-67
references: 10438153
references: Clin Exp Immunol. 2000 Oct;122(1):20-7
references: 11012613
references: Blood. 2003 Jan 15;101(2):585-93
references: 12393559
references: Ophthalmology. 2009 Jul;116(7):1356-9
references: 19450879
references: Arch Ophthalmol. 1966 May;75(5):689-92
references: 5936375
references: Ophthalmology. 2003 Apr;110(4):681-6
references: 12689886
references: Exp Neurol. 1996 Jul;140(1):43-52
references: 8682178
references: J Ocul Pharmacol Ther. 2011 Jun;27(3):265-71
references: 21574867
references: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):304-9
references: 15623789
references: Ophthalmology. 1984 Jun;91(6):564-79
references: 6462622
references: Arch Ophthalmol. 1992 Feb;110(2):259-66
references: 1736876
references: Trans Ophthalmol Soc U K. 1978 Apr;98(1):63-5
references: 373174
references: J Neuropathol Exp Neurol. 1996 Jun;55(6):722-8
references: 8642398
references: Arch Ophthalmol. 1974 Oct;92(4):312-4
references: 4414887
references: Int J Pharm. 2013 Jan 30;441(1-2):507-15
references: 23149258
references: Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):80-6
references: 20702826
references: J Immunol. 1991 Feb 1;146(3):1072-6
references: 1988495
references: Invest Ophthalmol Vis Sci. 1994 Jan;35(1):281-94
references: 8300356
references: Arch Ophthalmol. 1974 May;91(5):373-6
references: 4821791
references: Exp Eye Res. 1999 May;68(5):583-90
references: 10328972
references: Am J Ophthalmol. 2004 Mar;137(3):560-2
references: 15013884
references: Exp Eye Res. 1998 May;66(5):521-9
references: 9628799
references: Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1769-80
references: 11431441